KR102110966B1 - 데옥시포도필로톡신의 대량생산 방법 - Google Patents
데옥시포도필로톡신의 대량생산 방법 Download PDFInfo
- Publication number
- KR102110966B1 KR102110966B1 KR1020180051133A KR20180051133A KR102110966B1 KR 102110966 B1 KR102110966 B1 KR 102110966B1 KR 1020180051133 A KR1020180051133 A KR 1020180051133A KR 20180051133 A KR20180051133 A KR 20180051133A KR 102110966 B1 KR102110966 B1 KR 102110966B1
- Authority
- KR
- South Korea
- Prior art keywords
- deoxypodophyllotoxin
- methanol
- extraction
- column
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 80
- 238000000605 extraction Methods 0.000 claims abstract description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 99
- ZGLXUQQMLLIKAN-UHFFFAOYSA-N Deoxypicropodophyllin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3CC3C2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-UHFFFAOYSA-N 0.000 claims description 66
- ZGLXUQQMLLIKAN-SVIJTADQSA-N deoxypodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 ZGLXUQQMLLIKAN-SVIJTADQSA-N 0.000 claims description 61
- 239000000284 extract Substances 0.000 claims description 27
- 229920005989 resin Polymers 0.000 claims description 26
- 239000011347 resin Substances 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 241000218691 Cupressaceae Species 0.000 claims description 3
- 241000721662 Juniperus Species 0.000 claims description 3
- 229920001429 chelating resin Polymers 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 20
- 239000002904 solvent Substances 0.000 abstract description 14
- 238000000926 separation method Methods 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 11
- 229940093499 ethyl acetate Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 238000003808 methanol extraction Methods 0.000 description 10
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 5
- 239000000401 methanolic extract Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001256603 Bridelia tulasneana Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 240000005308 Juniperus chinensis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000409991 Mythimna separata Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000206469 Pulsatilla Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
도 2는 본 발명의 실시예 1-2에 따라 추출된 메탄올 추출물, Diaion HP-20 수지 통과액 및 100% 메탄올 용출액과 데옥시포도필로톡신 표준물질의 고성능액체크로마토그래피(HPLC) 그래프를 비교한 것을 나타낸 도이다.
도 3은 본 발명의 실시예 1-2에 따라 Diaion HP-20 수지의 100% 메탄올 용출액에서는 머무름 9분에 나타나는 물질을 1H-NMR으로 분석한 결과를 나타낸 도이다.
도 4는 본 발명의 실시예 1-2에 따라 분리, 정제된 데옥시포도필로톡신의 항암효과를 MTT 실험방법을 통해 확인한 결과를 나타낸 도이다.
도 5는 본 발명의 실시예 2에 따라 Diaion HP-20 수지 및 에탄올 용액을 이용하여 전호로부터 대량으로 데옥시포도필로톡신을 추출하는 방법을 간략화한 도이다.
도 6은 본 발명의 실시예 2에 따라 추출된 에탄올 추출물, Diaion HP-20 수지 통과액 및 100% 에탄올 용출액과 데옥시포도필로톡신 표준물질의 고성능액체크로마토그래피(HPLC) 그래프를 비교한 것을 나타낸 도이다.
도 7은 본 발명의 실시예 2에 따라 Diaion HP-20 수지의 100% 에탄올 용출액에서는 머무름 9분에 나타나는 물질을 1H-NMR으로 분석한 결과를 나타낸 도이다.
추출 방법 | 추출물의 고형분 함량 |
부탄올 추출물의 고형분 함량 |
부탄올 추출물의 데옥시포도필로톡신 함량 |
수율 (%) (DPT/고형분) |
열수 추출 | 2.95 g | 0.12 g | 15.95 mg | 0.54 |
50% 메탄올 추출 | 2.67 g | 0.14 g | 67.20 mg | 2.52 |
100% 메탄올 추출 | 1.57 g | 0.15 g | 66.79 mg | 4.25 |
정제법 | 초기 전호의 양 | 추출물의 고형분 함량 |
최종 추출물의 고형분 함량 |
최종 추출물의 DPT 함량 |
순도 (%) (DPT/고형분) |
비교예 1 | 500 g | 79 g | 52 mg | 50 mg | >95 순수분리) |
실시예 1-2 | 10 kg | 1,065g | 37 g | 29.7 g | 80 |
정제법 | 초기 전호의 양 | 추출물의 고형분 함량 |
최종 추출물의 고형분 함량 |
최종 추출물의 DPT 함량 |
순도 (%) (DPT/고형분) |
비교예 2 | 500 g | 79 g | 52 mg | 50 mg | >95 순수분리) |
실시예 2 | 30 kg | 3,197g | 125.2 g | 100.6 g | 80 |
Claims (4)
- 추출 대상물의 80 부피% 알코올 추출액을 활성탄, Diaion HP-20 수지 및 Amberlite XAD-20 수지로 이루어진 군에서 선택되는 충전제로 충전된 크로마토그래피 칼럼에 통과시켜 데옥시포도필로톡신을 칼럼에 흡착시키는 단계;
80 부피% 알코올을 상기 칼럼에 통과시켜 흡착되지 않은 물질을 용출시키는 단계;
100 부피% 알코올을 상기 칼럼에 통과시켜 흡착되어 있던 데옥시포도필로톡신을 용출시키는 단계;를 포함하며,
상기 알코올은 메탄올 또는 에탄올이고,
상기 추출 대상물은 전호, 백두옹, 향나무, 측백나무, 나한백 및 토밀수로 이루어진 군에서 1종 이상 선택되는 것인,
데옥시포도필로톡신의 추출 방법. - 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170059379 | 2017-05-12 | ||
KR1020170059379 | 2017-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180124733A KR20180124733A (ko) | 2018-11-21 |
KR102110966B1 true KR102110966B1 (ko) | 2020-05-14 |
Family
ID=64602224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180051133A Active KR102110966B1 (ko) | 2017-05-12 | 2018-05-03 | 데옥시포도필로톡신의 대량생산 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102110966B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102378151B1 (ko) * | 2020-05-11 | 2022-03-24 | 주식회사 제이앤씨사이언스 | 베타-아포피크로포도필린의 신규한 유도체 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100515206B1 (ko) * | 2002-09-23 | 2005-09-16 | 김종석 | 백두옹 추출물을 주성분으로 함유하는 미백 화장용 조성물 |
KR100980400B1 (ko) * | 2003-09-02 | 2010-09-07 | 에스케이케미칼주식회사 | 치매치료 효과를 갖는 백두옹 추출물 |
KR20110012431A (ko) * | 2009-07-30 | 2011-02-09 | 한국화학연구원 | 도라지 또는 도라지 추출물로부터의 순도 및 유효 사포닌 함량이 증가된 조사포닌 조성물의 제조방법 |
KR101429197B1 (ko) * | 2010-11-23 | 2014-09-25 | 대한민국 | 전호 추출물을 포함하는 항균 조성물 |
-
2018
- 2018-05-03 KR KR1020180051133A patent/KR102110966B1/ko active Active
Also Published As
Publication number | Publication date |
---|---|
KR20180124733A (ko) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Manzoor et al. | Novel extraction techniques and pharmaceutical activities of luteolin and its derivatives | |
DK1734949T3 (en) | Remediation of ellagitannins | |
Wang et al. | Isolation, purification and identification of antioxidants in an aqueous aged garlic extract | |
CN104825500B (zh) | 白肉灵芝提取物、提取方法及其用途 | |
EP2329816A1 (en) | An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof | |
KR102277523B1 (ko) | 칸나비스 식물로부터 칸나비디올을 연속으로 제조하는 방법 및 그 용도 | |
CN105294623B (zh) | 一种倍半萜内酯类化合物、其制备方法以及应用 | |
Heng et al. | Analysis of the bioactive components of Sapindus saponins | |
CN105935363A (zh) | 组合物、藏红花色素类活性部位及其用途 | |
CN107412221A (zh) | 一种牡丹籽提取物及其作为抗肿瘤药物的应用 | |
KR102110966B1 (ko) | 데옥시포도필로톡신의 대량생산 방법 | |
KR101080648B1 (ko) | 쑥속(Artemisia species)식물의 추출물로부터 원심향류분배 크로마토그래피를 이용한 고농도 유파티린(Eupatilin) 및 자세오시딘(Jaceosidine)을 대량으로 분리 및생산하는 방법 | |
CN105693806A (zh) | 一种二甲磺酸阿米三嗪的药物组合物及其医药用途 | |
KR101973372B1 (ko) | 엘라그산을 함유하는 복분자 추출물의 제조방법 및 엘라그산의 분리방법 | |
Erukainure et al. | Translational suppression of SARS-COV-2 ORF8 protein mRNA as a Viable therapeutic target against COVID-19: Computational studies on potential roles of isolated compounds from Clerodendrum volubile leaves | |
CN107708717B (zh) | 白鹤灵芝醌c作为神经细胞凋亡抑制剂的应用 | |
CN110872337B (zh) | 一种从迷迭香中同时制备不同高纯度三萜酸的方法 | |
CN104447655A (zh) | 阿魏中的新倍半萜香豆素及其制备方法和医疗用途 | |
CN104857245B (zh) | 紫萼玉簪花总皂苷的制备方法和应用 | |
CN104478686A (zh) | 姜黄挥发油中芳姜黄酮对照品的制备方法 | |
CN100404524C (zh) | 高纯度蛇床子素及其制备方法和以该化合物为活性成分的药物组合物 | |
CN102070573B (zh) | 一种具有抗肿瘤活性的单四氢呋喃型番荔枝内酯化合物及其应用 | |
Lim et al. | Improvement of the Fractional Precipitation Process for the Purification of (+)-dihydromyricetin | |
CN101618069B (zh) | 一种兼治瘀肿、出血和镇痛的胶囊制剂,其制备方法及用途 | |
CN105061455B (zh) | 一种可同时大量分离高纯度藤黄酸和新藤黄酸的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180503 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190517 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20191112 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200401 |
|
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200508 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200508 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20240423 Start annual number: 5 End annual number: 5 |